Adial pharmaceuticals regains compliance with nasdaq listing requirement

Charlottesville, va., nov. 29, 2023 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from nasdaq today that the company has regained compliance with nasdaq listing rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000. nasdaq will continue to monitor the company's ongoing compliance with the stockholders' equity requirement and, if at the time of its next periodic report the company does not evidence compliance, it may be subject to delisting.
ADIL Ratings Summary
ADIL Quant Ranking